Research prototype, not medical advice.

In a phase 2 trial (about 218 people aged 65+), 6 weeks of low-dose everolimus raised flu vaccine response by about 20%.

Confidence
Established
Level of evidence
Randomized clinical trial
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Deregulated nutrient sensingRapamycin (and analogues: everolimus)mTOR (mTORC1)

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports mTOR inhibition improves immune function in the elderly
Mannick et al. · Science Translational Medicine 2014
— Verified